

Aurangabad, 14<sup>th</sup> August, 2019

**Wockhardt Q1FY20 sales at Rs. 863 crore,  
 EBITDA up by 93% in Q1 FY 20 at Rs.56 crore**

	Q1-FY20	Q4-FY19	Q1-FY19
	Apr - Jun 2019	Jan - Mar 2019	Apr - Jun 2018
	INR Cr	INR Cr	INR Cr
<b>Sales</b>	<b>863</b>	<b>979</b>	<b>1,008</b>
<b>EBITDA before R&amp;D*</b>	<b>116</b>	<b>103</b>	<b>90</b>
<b>EBITDA % to Sales</b>	<b>13.5%</b>	<b>10.6%</b>	<b>8.9%</b>
<b>R&amp;D</b>	<b>60</b>	<b>69</b>	<b>61</b>
<b>R&amp;D % to Sales</b>	<b>7.0%</b>	<b>7.0%</b>	<b>6.1%</b>
<b>EBITDA*</b>	<b>56</b>	<b>35</b>	<b>29</b>
<b>EBITDA Margins %</b>	<b>6.5%</b>	<b>3.6%</b>	<b>2.9%</b>
<b>PBT</b>	<b>(78)</b>	<b>(48)</b>	<b>(100)</b>
<b>Profit After Tax</b>	<b>(45)</b>	<b>(14)</b>	<b>(86)</b>
<b>PAT Margins %</b>	<b>-5.2%</b>	<b>-1.4%</b>	<b>-8.5%</b>
<b>EPS (Rs)</b>	<b>(4.1)</b>	<b>(1.3)</b>	<b>(7.8)</b>

\*Inclusive of impact of IND AS 116 (Lease Accounting) in Q1 FY20.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1<sup>st</sup> Quarter Results for Financial Year 2019-20, today.

**Business review for the quarter:**

The business performance of the Company during the quarter ended 30<sup>th</sup> June, 2019 showed improvement in EBITDA by 93% from Rs.29 crore in Q1 FY19 to Rs. 56 crore in Q1 FY20 driven by Remedial cost reduction and overall cost rationalisation. EBITDA in Q1 FY20 is inclusive of impact of IND AS 116 (Lease Accounting) as applicable.

Sales during Q1 FY20 were at Rs. 863 crore lower by 14% as compared to corresponding quarter of previous year.

The focus in strategic R&D initiatives of the Company in the global arena continued to remain one of the key priorities. Such strategic R&D expenses though meant for the future are expensed off.

**US Business** continued to remain steady at Rs.186 crore in Q1FY20 as compared to Rs.182 crore in Q1FY19 . US Business contributed 22% of the Global Revenue.

**Emerging Market Business** of the Company witnessed growth of 21% in Q1FY20 over Q1FY19 and contributed about Rs.144 crore. (about 17% of the Global Revenue)

**UK Business** during the quarter de-grew by 6% and stood at Rs.225 crore. UK Business contributed about 26% of Global Revenue.

**Irish Business** de-grew by 14% to Rs.38 crore in Q1FY20 as compared to Q1FY19.

**Total EU Business** contributed 33% of the Global Revenue.

**India Business** stood at Rs.244 crore in Q1FY20 as compared to Rs.395 crore in Q1FY19 de-grew by 38% mainly on account of lower sales in Quality Generics division and in some of the therapeutic areas. India Business contributed 28% of the Global Revenue.

Research & Development expenditure during the quarter was at Rs.60 crore (7% to sales) and including capital expenditure is at 12% to sales.

Capital expenditure during the quarter was Rs.50 crore.

#### **Debt Repayment :**

During the quarter the Company repaid Rs. 351 crore towards various Long term debts obligations as per schedule. Total Long term outstanding debts as on 30<sup>th</sup> June, 2019 was Rs. 2,119 crores as compared to Rs. 2,723 crores as on 30<sup>th</sup> June, 2018. Gross Debt- Equity ratio as on 30<sup>th</sup> June, 2019 stood at 0.91.

**Intellectual Property (IP) :**

The company's continued pursuit in creating strong **Intellectual Property (IP)** base resulted into filing of 11 patents **during the Quarter ended 30<sup>th</sup> June, 2019** taking the cumulative filings to 3,143. The company was granted 5 patents during the quarter and now holds 699 patents.

**About Wockhardt :**

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 7,000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 72% of its global revenues coming from international businesses.